

# **2023 Summer Symposium and Reception**

### Saturday, June 3, 2023, 5:30 pm – 10:00 pm

The Metropolitan in Willis Tower 233 South Wacker Drive, 66th Floor Chicago, Illinois 60606

# Chinese American Hematologist & Oncologist Network (CAHON)



#### **Meeting Organizers**

RuiRong Yuan, MD, PhD – CAHON Board Chair Bo Zhao, MD – CAHON President Zhaohui Jin, MD – Mayo Clinic Tian Zhang, MD, MHS – UT Southwestern Comprehensive Cancer Center J Christine Ye, MD – MD Anderson Cancer Center Iris Zhi, MD, PhD – Memorial Sloan Kettering Cancer Center

www.cahon.org

**2023 Corporate Partners** 







**2023 Annual Oncology Supporters** 



**Exhibitors** 











# Visit the AstraZeneca Booth to learn more



IMFINZI, IMJUDO, and TAGRISSO are registered trademarks of the AstraZeneca group of companies. ©2023 AstraZeneca. All rights reserved. US-74239 3/23

#### CONTENTS

Event Sponsors
About CAHON page 4
Upcoming CAHON Events page 6
Program page 7
About Our Speakers page 8
CAHON Young Investigator Awards page 9



#### **ABOUT CAHON**

Founded by Chinese American Hematologists and Oncologists in 2005, the primary missions of CAHON are to foster communications amongst Chinese American medical professionals for the delivery of high-quality health care to patients with neoplastic and hematological diseases, and to promote medical information exchange between the United States and China in the field of hematology and oncology. CAHON strives to serve as a bridge among its members and between Chinese and American Hematology-Oncology communities for medical and educational exchange.

#### THE STORY BEHIND THE LOGO

CAHON'S logo was designed by Drs. Weijing Sun, Ke Liu, and Jeffrey Ye, under the supervision of the CAHON Board. The design has the following elements and takes the following considerations:

- The overall shape represents the globe.
- The blue, white, red and yellow represent the colors of two nations' flags. China and the US.
- The yellow and red stripes above the blue, represent bridges. One of CAHON's key missions is to serve as a bridge between Chinese American Hematology-Oncology communities for medical and educational exchange.
- The white space is in the shape of a heart. The hearts of our members continue to drive our mission to provide high quality patient care to everyone.

#### **CAHON MEMBERSHIP**

By joining CAHON you will have access to:

- A growing network of Chinese American professionals working in your field;
- A private WeChat group where you can submit clinical questions to respected colleagues who are knowledgeable in specific areas of hematology and oncology;
- Reduced or waived registration fees for all CAHON events and meetings along with priority hotel reservations;
- Members-only section of the CAHON website featuring the member directory; and
- Travel award opportunities.

#### **MEMBERSHIP CATEGORIES**

Regular/Active Membership Associate Membership Allied Membership

Visit cahon.org/membership for more information on membership.









# SCAN TO DISCOVER MORE

CABOMETYXhcp.com

#### 10<sup>th</sup> ANNUAL NEW YORK ONCOLOGY FORUM (NYOF)

October 7-8, 2023 Sheraton La Guardia East Flushing, NY

The CAHON annual New York Oncology Forum (NYOF) is a one and a half day educational program that includes presentations on new developments and updates from the latest ASH, ASCO and SITC meetings including novel agents for Hematology and Oncology. 2023 will mark the 10<sup>th</sup> anniversary for this annual event and it draws more than 100 clinicians, researchers, medical students, clinical fellows as well as laboratory and health care related scientists working in hematology and oncology.

#### WINTER SYMPOSIUM AND RECEPTION

#### December 9, 2023 University Club Atop Symphony Tower San Diego, CA

Held in conjunction with ASH, the Winter Symposium will offer expert perspectives and practical insights on current advancements in a variety of cancer treatments, as well as foster collaboration and provide a forum for interaction and collaboration between hematologists and oncologists.



# Meeting Agenda

7:00 – 7:30 pm	CAHON Presentations Opening Remarks and Introduction of VIP Guests RuiRong Yuan, MD, PhD – Board Chair
	CAHON Presidential Address and CAHON Updates Bo Zhao, MD – President
	<b>Updates on CAHON Journals</b> Delong Liu, MD, PhD – <i>Editor-in-Chief, Journal of Hematology &amp; Oncology</i>
7:30 – 8:15 pm	Scientific Presentations
7:30 – 7:45	Introduction of the Prostate Cancer Foundation William K. Oh, MD – Chief Medical Officer, Executive Vice President Prostate Cancer Foundation
7:45 – 8:00	National Comprehensive Cancer Network - Global Programs, and initiatives to facilitate and enhance cancer care in China Wui-Jin Koh, MD – Chief Medical Officer National Comprehensive Cancer Network
8:00 - 8:15	<b>Clinical Trials in China – Oncology Perspective</b> Shun Lu, MD, PhD – Chief of Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiaotong University
8:15 – 8:30 pm	<b>Young Investigator Awards Ceremony 💭</b> J Christine Ye, MD   Zhaohui Jin, MD   Tian Zhang, MD, MHS  Wanqing Iris Zhi, MD, PhD
	CAHON 2022-2024 Academic Committee Every year, several Young Investigator Awards are awarded to CAHON early career or physician-in-training members in hopes of fostering growth and achievement. The award is based on the scientific merit of abstracts accepted to either the American Society of Clinical Oncology ASCO) Annual Meeting or the American Society of Hematology (ASH).
	Congratulations to the Young Investigator Award winners!
8:30 – 8:40 pm	Closing Remarks Ruirong Yuan, MD, PhD – Board Chair
8:40 – 10:00 pm	Social Gathering

# **Speakers**



**Dr. William K. Oh** is Chief Medical Officer at the Prostate Cancer Foundation (PCF), the world's leading philanthropic organization dedicated to the eradication of prostate cancer and is also a Clinical Professor of Medicine in the Division of Hematology and Medical Oncology at The Tisch

Cancer Institute of the Icahn School of Medicine at Mount Sinai. He is an expert in the management of genitourinary malignancies, including prostate, renal, bladder and testicular cancers. Prior to joining PCF, he was the Chief Medical Officer at Sema4, a patient-centered health intelligence company for 2 years. From 2009-2020, Dr. Oh was Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute, an NCI-designated cancer center, at Mount Sinai. He spent 14 years at Harvard Medical School and Dana-Farber Cancer Institute in Boston, including service as Clinical Director of GU Oncology and Associate Professor of Medicine.

Dr. Oh has authored more than 350 original articles, reviews and book chapters on topics relating to prostate, renal, bladder and testicular cancers. He has edited 3 books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology (ASCO), the American Cancer Society (ACS) and the American Urological Association (AUA), including the Guidelines Committee for Castration Resistant Prostate Cancer. In addition to reviewing for prominent journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Cancer. He was inducted into the prestigious American Society for Clinical Investigation (ASCI) and has been repeatedly selected as a Top Doctor in New York Magazine, Castle Connolly, Best Doctors and Super Doctors.

Dr. Oh received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women's Hospital in Boston. Dr. Oh subsequently completed a fellowship in medical oncology at the Dana-Farber Cancer Institute in 1997.



**Dr. Wui-Jin Koh** is the Senior Vice President/Chief Medical Officer at the National Comprehensive Cancer Network (NCCN). In this role, Dr. Koh helps oversee the flagship NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) program. In addition, he is responsible for medical

leadership and oversight for NCCN's continuing medical education program, and represents the organization at clinical and scientific meetings. Prior to his role at NCCN, he served as Professor of Radiation Oncology at University of Washington and Medical Director for Radiation Oncology at Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance. Dr. Koh earned his medical degree at Loma Linda University School of Medicine. He conducted his post-graduate training at the University of Washington Medical Center, completing a residency and internship in radiation oncology and a clinical fellowship in tumor imaging. He is board-certified in radiation oncology.



**Shun Lu, MD, Ph.D.,** is the Professor, Chief of Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiaotong University and currently serves as associate editor for Journal of Thoracic Oncology, Lung Cancer, and editor for The Oncologist. Professor. Lu is the

committee member of ASCO (American Society of Clinical of Clinical Oncology) Asia Pacific Regional Council. He is also a committee member of the International Lung Cancer Research Association. He is the executive board member of Oncology Society Chinese Medical Association. He is also the executive board member of CSCO (Chinese Society of Clinical of Clinical Oncology) and the past chair of Chinese Lung Cancer Association. Professor Lu's other appointment include past director of Oncology Society Chinese Medical Association Shanghai Branch. He completed his Fellowship of Clinical Oncology in Tel Viv University, Israel, 1996-1997. Further he received the position of Visiting Professor in the Department of Thoracic/Head and Neck Medical oncology at the University of Texas MD Anderson Cancer in Houston, Texas, USA from 2004-2005.

Professor Lu served as the leading PI for more than 80 multicenter Phase III oncology clinical trials and participated as the key contributor for more than 70 global and regional clinical trials as well. He has authored more than 200 peer-reviewed articles, many of which has published at Lancet Oncology, JCO, Lancet Respiratory Medicine, Annuals of Oncology, PNAS, Clinical Cancer Research, Chest and JTO etc. (total IF: 889.9)

# **YIA Recipients**



**Dr. Lei Deng** is a third-year fellow of Hematology/ Oncology at Roswell Park Cancer Center and an incoming assistant professor at University of Washington/Fred Hutchinson Cancer Center. He has been interested in thoracic oncology since he was a medical student in West China School of

Medicine, Chengdu when he was mentored by Dr. You Lu. His research focus in Seattle will be neoadjuvant and/or adjuvant treatment for non-small cell lung cancer and cancer vaccine. This study extracted pseudo-individual patient data from anti-PD-1 clinical trials of melanoma and described the further risk of progression or death among patients who have been progression-free for more than 2 years. The results showed that no more than 4.0% of these patients had disease progression or death in any quarters, and the imaging surveillance interval can be extended to every 6 to 12 months.



**Dr. Emily Liang** is a first-year hematology/ oncology fellow at the University of Washington and Fred Hutchinson Cancer Center. Her research interests are in acute leukemia, transplantation, and cellular therapy.



**Dr. Dani Ran Castillo** is a third-year hematology/ oncology fellow preparing to pursue a career in GI Oncology at the City of Hope in California. With a keen interest in translational research, specifically in molecular biology and the study of claudins,

she will contribute to the field of GI Oncology. By investigating the role of claudins in disease progression and participating in clinical trials, with the hope to uncover new insights and develop innovative approaches for managing GI cancers. Joining the esteemed City of Hope, she looks forward to collaborating with experts and making meaningful contributions to improve patient outcomes in GI Oncology.



**Dr. Lawrence Liu** is a 1st year Hematology/ Oncology Fellow at City of Hope. He is interested in the areas of CAR T therapy and BiTE for Multiple Myeloma. He is also interested in identifying risk factors and preventive factors for MGUS to Myeloma progression.

## Notes



# See the latest data for **SARCLISA + Kd**

Explore the full results of the IKEMA phase 3 trial at **sarclisahcp.com** 



Kd=Kyprolis (carfilzomib) and dexamethasone

#### THE MOST THREATENING

EGFR MUTATION MAY BE THE ONE YOU DON'T SEE

Exon 20 insertion mutations in EGFR+ mNSCLC are more elusive and life-threatening than common EGFR mutations.1-11

These mutations differ from common mutations\* in how they are detected and treated, leaving patients at risk of disease progression.1-11

Don't leave patients with mNSCLC at risk.

#### EXPLORE MORE AT HIDDENEGFRTHREATS.COM

References: 1. Chiang AC, Fernandes AW, Pavilack M, et al. EGFR mutation testing cancer. References: 1. Chiang AC, Fernandes AW, Pavilack M, et al. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. *Nat Med.* 2018;24(5):638-646. **3**. Riess JW, Gandara DR, Frampton GM, et al. Diverse *EGFR* Exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. *J Thorac Oncol.* 2018;31(0):1560-1566. **4**. Arcial MF, Nafa K, Chaf JE, et al. *EGFR* exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. *Mol Cancer Ther.* 2013;12(2):270-229. **5**. Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring *EGFR* exon 20 insertions. *J Thorac Oncol.* 2013;8(2):179-184. **6**. Naidoo J, Sima C, Rodriguez K, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. *Cancer.* 2015;121(18):3212-3220. 7, Chen D, Song Z, Cheng G, Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring *EGFR* exon 20 mutations. *J Cancer.* 2015;21(18):3212-3220. 7, Chen D, Song Z, Cheng G, Clinical efficacy of first-generation EGFR-TKIs in patients with advanced ultcomes for patients with advanced NSCLC harboring *EGFR* exon 20 insertion mutations and common *X*. *Viter* **5**, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring *EGFR* exon 20 insertion mutations and common *EGFR* mutations. *Lung Cancer.* 2021;162:154-161. **9**. Bauml J, Viteri S, Minchom A, et al. Underdiagnosis of *EGFR* exon 20 insertion mutation variants: estimates from NGS-based real-world datasets. Presented at: the IASLC 2020 World Conference on Lung cancer. January 28-31, 2021. Singapore. **10** 





Chinese American Hematologist and Oncologist Network (CAHON) 555 East Wells Street, Suite 1100 • Milwaukee, WI 53202 USA Phone: 1 414-918-9890 • Fax: 1 414-276-3349